Mercury Laboratories Ltd
BSE:538964
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (74), the stock would be worth ₹595.18 (21% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 93.2 | ₹750 |
0%
|
| 3-Year Average | 74 | ₹595.18 |
-21%
|
| 5-Year Average | 26.7 | ₹214.95 |
-71%
|
| Industry Average | 44.8 | ₹360.35 |
-52%
|
| Country Average | 49.7 | ₹400.16 |
-47%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Mercury Laboratories Ltd
BSE:538964
|
900m INR | 93.2 | 19.1 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 45.4 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Mercury Laboratories Ltd
Glance View
Mercury Laboratories Ltd. engages in the production and sale of pharmaceuticals and its related products. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2015-02-23. The firm is engaged in the manufacturing of pharmaceuticals, medicinal drugs and formulations. The Company’s products include Analgesic, Anti-inflammatory, Anti-pyretic, Anthelmintic, Antibiotic, Anti-coagulant, Anti- platelet, Bleeding agents, Anti-fungal, Anti-hypertensive drugs, Anti-malarial drugs, Cardiovascular System, Central Nervous System, Eye, Gastro-intestinal system, Hypoglycemic (Anti-diabetic), Multivitamin, Protein supplement, Respiratory System, Anti- allergic, Steroids, Urinary system, Uterine stimulant and Miscellaneous. Its products also include Gynec, Paediatric, Surgeon, Physician, Antihypertensive (PIH), PCOS & Uterine Disorders, Galactagogue, Haemostat, Iron and Vitamins, Preterm Labor Management, Antiemetic, Dexamethasone Tablet, Glucosamine Sulphate, Prednisolone Acetate Ophthalmic Suspension USP, Ketorolac Tromethamine 0.4% Eye Drops and Ketorolac Tromethamine 0.4% Eye Drops.
